End-organ protection in cardiac surgery

被引:0
|
作者
De Somer, F. [1 ]
机构
[1] Univ Hosp Ghent, Ctr Heart, Ghent, Belgium
关键词
Cardiac surgery; Multiple organ failure; Cardiopulmonary bypass; SYSTEMIC INFLAMMATORY RESPONSE; CARBON-DIOXIDE DIFFERENCE; BYPASS GRAFT-SURGERY; ACUTE KIDNEY INJURY; OPEN-HEART-SURGERY; CARDIOPULMONARY BYPASS; OXYGEN DELIVERY; OFF-PUMP; CARDIOTOMY SUCTION; NITRIC-OXIDE;
D O I
暂无
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Mortality and morbidity postcardiac surgery with cardiopulmonary bypass (CPB) remain relative stable over the last decades, while the number of patients with increased comorbidity and more complex cardiac disease increases. Nevertheless, end-organ dysfunction and/or failure remain an issue. Multiple perioperative variables, such as non-optimal oxygen delivery, manipulation of the aorta, hyperlactatemia, type of anesthesia, surgical procedure and myocardial protection can be hold responsible for end-organ failure postcardiac surgery. However, it becomes more and more evident that also pre-existing factors, such as metabolic syndrome, renal insufficiency, hypertension, stroke and infection exacerbate mortality and morbidity. Unfortunately, these predisposing risk factors cannot be influenced perioperatively. Therefore, therapy should focus on controlling perioperative variables that, in combination with the predisposing factors, will further exacerbate organ dysfunction. In order to achieve this, more emphasis should be given to a patient-specific, goal-directed perfusion approach. This review will mainly focus on the impact of perioperative variables.
引用
收藏
页码:285 / 293
页数:9
相关论文
共 50 条
  • [1] Angiotensin II receptor blockade and end-organ protection
    Chung, O
    Unger, T
    AMERICAN JOURNAL OF HYPERTENSION, 1999, 12 (12) : 150S - 156S
  • [2] Combination therapy for antihypertensive patients: focused on end-organ protection
    Mizuno, Makoto
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2011, 115 : 37P - 37P
  • [3] The telmisartan Programme of Research tO show Telmisartan End-organ proteCTION (PROTECTION) Programme
    Weber, M
    JOURNAL OF HYPERTENSION, 2003, 21 : S37 - S46
  • [4] END-ORGAN DEAFNESS
    SIMONTON, KM
    ARCHIVES OF OTOLARYNGOLOGY, 1955, 61 (06): : 712 - 713
  • [5] Telmisartan: from lowering blood pressure to end-organ protection
    Schupp, Michael
    Unger, Thomas
    FUTURE CARDIOLOGY, 2005, 1 (01) : 7 - 15
  • [6] Losartan and end-organ protection-lessons from the RENAAL study
    Kowey, PR
    Dickson, TZ
    Zhang, ZX
    Shahinfar, S
    Brenner, BM
    CLINICAL CARDIOLOGY, 2005, 28 (03) : 136 - 142
  • [7] Providing end-organ protection with RAS inhibition: The evidence so far
    Weir, MR
    AMERICAN JOURNAL OF HYPERTENSION, 2005, 18 (05) : 265A - 266A
  • [8] Acetophenone protection against cisplatin-induced end-organ damage
    Geohagen, Brian
    Zeldin, Elizabeth
    Reidy, Kimberly
    Wang, Tao
    Gavathiotis, Evripidis
    Fishman, Yonatan, I
    LoPachin, Richard
    Loeb, David M.
    Weiser, Daniel A.
    TRANSLATIONAL ONCOLOGY, 2023, 27
  • [9] End-organ damage in hyperlipidemias
    Faust, M
    Krone, W
    INTERNIST, 2003, 44 (07): : 831 - +
  • [10] End-organ damages in Diabetes
    Haller, H.
    Strauer, B. E.
    INTERNIST, 2011, 52 (05): : 493 - 494